Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharma boss and ex-Teva CEO shine light into Israeli life science investor Bio-Light

This article was originally published in Scrip

Executive Summary

It's not every day that you hear of Teva Pharmaceutical Industries' ex-CEO, Israel Makov, and Sun Pharma's founder chairman and managing director, Dilip Shanghvi, becoming co-investors in a life science technology investment firm.

You may also be interested in...



Cipla Opens Up To Crowd Sourcing Innovation

Cipla has outlined its intent to incubate disruptive ideas in the healthcare space, along the lines of similar initiatives to accelerate innovation from US/European big pharma. It hopes that this "culture" will expand in India.

Aurobindo-Sandoz End $1bn US Deal

Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.

Takeda Gets New India Chief, Mandate To Broaden Access

Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.

Topics

Related Companies

UsernamePublicRestriction

Register

SC013967

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel